Cognitive stimulation software in depression project - COGSTIMD
Research type
Research Study
Full title
Cognitive stimulation software in depression project - COGSTIMD
IRAS ID
270273
Contact name
Chris Griffiths
Contact email
Sponsor organisation
Northamptonshire Healthcare NHS Foundation Trust
Duration of Study in the UK
1 years, 9 months, 1 days
Research summary
Clinical depression is the leading cause of disability worldwide (WHO, 2017). Over 50% of people do not experience remission after first-line antidepressant medication, and one-third do not after four courses of medication (Rush et al. 2006). Between 12%–20% of depressed patients have treatment resistant depression (TRD) (Nemeroff, 2007; Eaton, 2008).\nA person is referred to Northamptonshire Healthcare NHS Foundation Trust Neuromodulation Centre for depression by their GP or psychiatrist. The Neuromodulation Centre offers treatment options for TRD, including transcranial magnetic stimulation (TMS), ketamine (intravenous or oral) and ECT. \n\nPeople with depression often experience cognitive impairment (Lam et al. 2014). Depressed patients may experience deficits in working memory and attentional distortions in emotional processing and negative attention biases, which may contribute to maintaining their depressive state (Baune et al. 2018). It is important that services offer access to resources which may enhance cognitive function.\nMyCognition has invested over £5 million to develop a software program to assess and train cognitive functioning and provide health lifestyle information to support effective cognition. It was designed and built by cognitive scientists, has 18,000 user cases across ages, genders, health states and is CE Mark Class 1A Medical Device for intended purpose. It has been reviewed by NHS digital and defined as a ‘Trusted digital tool for patients and the public to manage and improve their health’. It has research evidence supporting its effectiveness and can be bought by anyone in the UK.\nAs a part of routine practice, over a period of 12 months Neuromodulation patients will be offered MyCognition. We will evaluate the impact of undertaking the software program on cognitive functioning and gain users feedback.\n
REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
19/YH/0362
Date of REC Opinion
23 Oct 2019
REC opinion
Unfavourable Opinion